You are here

Human Anti-WISP1 Antibodies for Treatment of Idiopathic Pulmonary Fbrosis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL122078-01A1
Agency Tracking Number: R43HL122078
Amount: $224,823.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
6042 CORNERSTONE CT, STE B
SAN DIEGO, CA 92121-4746
United States
DUNS: 832545805
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 GUNNAR KAUFMANN
 (858) 210-3705
 gkaufmann@sorrentotherapeutics.com
Business Contact
 HENRY JI
Phone: (858) 210-3701
Email: hji@sorrentotherapeutics.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): New anti-fibrotic drugs are needed to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, chronically debilitating clinical syndrome with unknown etiology and a terminal outcome. IPF symptoms include persistent cough, progressive severe shortness of breath and decreased exercise capacity. Up to 200,000 Americans suffer from this disease with expected survival limited to 3-5 years. There are currently no approved US drugs leaving lung transplantation as the only option to extend life. IPF is initially characterized by alveolar epithelial cell injury followed by epithelial-mesenchymal transition (EMT) and exaggerated fibroblast migration, activation and proliferation with extracellular matrix deposition and tissue remodeling. When a sufficient proportion of the IPF lung becomes scarred respiratory failure and comorbidities occur. WNT1- Inducible Signaling Protein-1 (WISP1; also known as CCN4) is an autocrine and paracrine extracellular stimulus for EMT. Stu

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government